» Articles » PMID: 33751421

Global Landscape of Clostridioides Difficile Phylogeography, Antibiotic Susceptibility, and Toxin Polymorphisms by Post-Hoc Whole-Genome Sequencing from the MODIFY I/II Studies

Abstract

Introduction: Clostridioides (Clostridium) difficile infection, the leading cause of healthcare-associated diarrhea, represents a significant burden on global healthcare systems. Despite being a global issue, information on C. difficile from a global perspective is lacking. The aim of this study is to model the global phylogeography of clinical C. difficile.

Methods: Using samples collected from the MODIFY I and II studies (NCT01241552, NCT01513239), we performed whole-genome sequencing of 1501 clinical isolates including 37 novel sequence types (STs), representing the largest worldwide collection to date.

Results: Our data showed ribotypes, multi-locus sequence typing clades, and whole-genome phylogeny were in good accordance. The clinical C. difficile genome was found to be more conserved than previously reported (61% core genes), and modest recombination rates of 1.4-5.0 were observed across clades. We observed a significant continent distribution preference among five C. difficile clades (Benjamini-Hochberg corrected Fisher's exact test P < 0.01); moreover, weak association between geographic and genetic distance among ribotypes suggested sources beyond healthcare-related transmission. Markedly different trends of antibiotic susceptibility among lineages and regions were identified, and three novel mutations (in pyridoxamine 5'-phosphate oxidase family protein: Tyr130Ser, Tyr130Cys, and a promoter SNP) associated with metronidazole-reduced susceptibility were discovered on a nim-related gene and its promotor by genome-wide association study. Toxin gene polymorphisms were shown to vary within and between prevalent ribotypes, and novel severe mutations were found on the tcdC toxin regulator protein.

Conclusion: Our systematic characterization of a global set of clinical trial C. difficile isolates from infected individuals demonstrated the complexity of the genetic makeup of this pathogenic organism. The geographic variability of clades, variability in toxin genes, and mutations associated with antibiotic susceptibility indicate a highly complex interaction of C. difficile between host and environment. This dataset will provide a useful resource for validation of findings and future research of C. difficile.

Citing Articles

Abundant geographical divergence of Clostridioides difficile infection in China: a prospective multicenter cross-sectional study.

Bai L, Xu T, Zhang W, Jiang Y, Gu W, Zhao W BMC Infect Dis. 2025; 25(1):185.

PMID: 39920584 PMC: 11806848. DOI: 10.1186/s12879-025-10552-y.


Whole-Genome Sequencing-Based Characterization of Infection Cases at the University Hospital Centre Zagreb.

Siroglavic M, Higgins P, Kanizaj L, Ferencak I, Juric D, Augustin G Microorganisms. 2025; 12(12.

PMID: 39770637 PMC: 11676685. DOI: 10.3390/microorganisms12122434.


Gut Microbiota and New Microbiome-Targeted Drugs for Infections.

Lee A, Yoo J, Yoon E Antibiotics (Basel). 2024; 13(10).

PMID: 39452261 PMC: 11505460. DOI: 10.3390/antibiotics13100995.


Genomic study of European ribotype 002/sequence type 8.

Dost I, Abdel-Glil M, Persson S, Conza K, Oleastro M, Alves F Microb Genom. 2024; 10(7).

PMID: 39051872 PMC: 11316560. DOI: 10.1099/mgen.0.001270.


infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.

Di Bella S, Sanson G, Monticelli J, Zerbato V, Principe L, Giuffre M Clin Microbiol Rev. 2024; 37(2):e0013523.

PMID: 38421181 PMC: 11324037. DOI: 10.1128/cmr.00135-23.


References
1.
Page A, Cummins C, Hunt M, Wong V, Reuter S, Holden M . Roary: rapid large-scale prokaryote pan genome analysis. Bioinformatics. 2015; 31(22):3691-3. PMC: 4817141. DOI: 10.1093/bioinformatics/btv421. View

2.
Baines S, Wilcox M . Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection. Antibiotics (Basel). 2016; 4(3):267-98. PMC: 4790285. DOI: 10.3390/antibiotics4030267. View

3.
Alauzet C, Aujoulat F, Lozniewski A, Marchandin H . A sequence database analysis of 5-nitroimidazole reductase and related proteins to expand knowledge on enzymes responsible for metronidazole inactivation. Anaerobe. 2018; 55:29-34. DOI: 10.1016/j.anaerobe.2018.10.005. View

4.
Janvilisri T, Scaria J, Thompson A, Nicholson A, Limbago B, Arroyo L . Microarray identification of Clostridium difficile core components and divergent regions associated with host origin. J Bacteriol. 2009; 191(12):3881-91. PMC: 2698405. DOI: 10.1128/JB.00222-09. View

5.
Tickler I, Goering R, Whitmore J, Lynn A, Persing D, Tenover F . Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013. Antimicrob Agents Chemother. 2014; 58(7):4214-8. PMC: 4068552. DOI: 10.1128/AAC.02775-13. View